Mer­ck KGaA pays Ab­bisko $85M for full com­mer­cial rights to be­nign tu­mor drug

Mer­ck KGaA is spend­ing $85 mil­lion to tap glob­al com­mer­cial­iza­tion rights to pim­i­co­tinib, a can­di­date for non-ma­lig­nant tu­mors that it li­censed from Chi­na’s Ab­bisko Ther­a­peu­tics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER